Fulgent CSO has 1,331 shares withheld for taxes

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding.

Accepted by SEC EDGAR 01/28/2026 - 05:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding. On January 26, 2026, 1,331 shares of common stock were withheld at $27.53 per share to cover taxes from vested restricted stock units. After this, Gao directly owned 951,559 shares of Fulgent Genetics common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 1,331 shares

Exercise Price or Tax Liability 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,331	$27.53	$37K

Holdings After Transaction: Common Stock — 951,559 shares (Direct)

Holdings Before and After: Common Stock, 952,890 to 951,559 shares (Direct)

Footnotes (1)

1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fulgent Genetics (FLGT) report for Hanlin Gao?

Fulgent Genetics reported that Chief Scientific Officer Hanlin Gao had 1,331 shares of common stock withheld on January 26, 2026 to satisfy tax obligations from vesting restricted stock units, at a price of $27.53 per share.

How many Fulgent Genetics (FLGT) shares does Hanlin Gao own after the transaction?

After the reported tax withholding, Chief Scientific Officer Hanlin Gao beneficially owned 951,559 shares of Fulgent Genetics common stock directly. This figure reflects ownership following the withholding of 1,331 shares to cover tax obligations linked to vested restricted stock units.

Was the Fulgent Genetics (FLGT) insider transaction an open market sale?

The filing describes shares withheld to satisfy tax obligations arising from vesting restricted stock units. The transaction code was "F", indicating tax withholding, rather than a discretionary open market sale by Chief Scientific Officer Hanlin Gao.

What was the price used for Hanlin Gao’s Fulgent Genetics (FLGT) tax withholding?

The 1,331 shares withheld from Chief Scientific Officer Hanlin Gao to satisfy tax obligations were valued at $27.53 per share. This price is used in the Form 4 to report the value of the non-discretionary tax withholding transaction.

What triggered the tax withholding transaction for Fulgent Genetics (FLGT) insider Hanlin Gao?

The withholding arose from the vesting of restricted stock units that were assumed under a prior merger agreement. When these units vested, 1,331 shares were withheld to cover tax obligations, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		F		1,331(1)	D	$27.53	951,559	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim as Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.